<SEC-DOCUMENT>0001048477-25-000049.txt : 20250501
<SEC-HEADER>0001048477-25-000049.hdr.sgml : 20250501
<ACCEPTANCE-DATETIME>20250501160818
ACCESSION NUMBER:		0001048477-25-000049
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250501
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250501
DATE AS OF CHANGE:		20250501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMARIN PHARMACEUTICAL INC
		CENTRAL INDEX KEY:			0001048477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				680397820
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-26727
		FILM NUMBER:		25903129

	BUSINESS ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
		BUSINESS PHONE:		4155066700

	MAIL ADDRESS:	
		STREET 1:		105 DIGITAL DRIVE
		CITY:			NOVATO
		STATE:			CA
		ZIP:			94949
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bmrn-20250501.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ed8860d5-ee22-4abf-911e-4fd9712009c9,g:31fbccfc-c739-4858-a702-763c43964974,d:d84f0e5931ca46d38ac31dcc684ffb2b-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bmrn-20250501</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001048477</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bmrn-20250501.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001048477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id84f0e5931ca46d38ac31dcc684ffb2b_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May&#160;1, 2025</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">BioMarin Pharmaceutical Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-26727</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">68-0397820</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">770 Lindaro Street</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">San Rafael</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94901</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Zip Code)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">415</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">506-6700</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:110%">(Registrant's telephone number, including area code)</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Not Applicable </span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric> </span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:30.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.032%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.390%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">BMRN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id84f0e5931ca46d38ac31dcc684ffb2b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May&#160;1, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March&#160;31, 2025. The Company&#8217;s press release issued on May&#160;1, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id84f0e5931ca46d38ac31dcc684ffb2b_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:14.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="earningsrelease-1may25ex991.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Press Release of the Company dated May&#160;1, 2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id84f0e5931ca46d38ac31dcc684ffb2b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:47.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.112%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc., <br/>a Delaware corporation</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date: May&#160;1, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ G. Eric Davis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">G. Eric Davis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Executive Vice President, Chief Legal Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>earningsrelease-1may25ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib1266994b1bd4e69bf80b8ec9b3834e1_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><img alt="imagea.jpg" src="imagea.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:230px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.994%"><tr><td style="width:1.0%"></td><td style="width:48.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Contact&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Investors&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Media&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Traci McCarty</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Marni Kottle</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">BioMarin Pharmaceutical Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(415) 455-7558</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(650) 374-2803</font></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First Quarter 2025 Total Revenues of $745 million (+15% Y&#47;Y and +17% at Constant Currency Y&#47;Y)</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y&#47;Y)</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y&#47;Y)</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Conference Call and Webcast Scheduled Today at 4&#58;30 p.m. ET</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SAN RAFAEL, Calif., May&#160;1, 2025 &#8211; BioMarin Pharmaceutical Inc. (NASDAQ&#58; BMRN) today announced financial results for the first quarter ended March&#160;31, 2025. </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;During the first quarter, we saw continued high demand for our innovative medicines resulting in strong revenue growth and profitability,&#8221; said Alexander Hardy, President and Chief Executive Officer of BioMarin. &#8220;Products in our pipeline also advanced according to plan. In April, we shared positive top-line results from the Phase 3 PALYNZIQ</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> study for the treatment of adolescents with phenylketonuria between the ages of 12 and 17. Also in April, we were pleased to conclude enrollment in the pivotal study in hypochondroplasia with VOXZOGO, keeping us on track to launch in 2027, should data be supportive.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Hardy continued, &#8220;For the remainder of 2025, we look forward to continued momentum in our global expansion of VOXZOGO</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for achondroplasia.  Across our Enzyme Therapies, we plan to build upon strong PALYNZIQ performance in the quarter, as well as initiatives to drive uptake of our other therapies to reach an even greater number of patients around the world. In addition to our strong financial outlook, we expect to advance multiple new indications with VOXZOGO in our CANOPY clinical program, share early clinical results from both BMN 351 for Duchenne Muscular dystrophy and BMN 333, our long-acting C-type natriuretic peptide, as well as execute on our business development strategy. We are delivering strong growth and profitability while we continue to implement BioMarin&#8217;s new strategy and operating model. We look forward to seeing the benefits of this transformation flow through our results in the coming quarters and beyond.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:5pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font><br></font></div><div style="margin-bottom:5pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">First Quarter 2025 Financial Highlights</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Total Revenues </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the first quarter of 2025 were $745 million, an increase of 15% compared to the same period in 2024, driven by strong 40% year-over-year VOXZOGO revenue growth from new patients initiating therapy across all regions. In the quarter, revenues from BioMarin&#8217;s Enzyme Therapies (</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ALDURAZYME</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, BRINEURA</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, NAGLAZ</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">YME</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, PALYNZIQ and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">VIMIZIM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) increased </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8%</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> compared to the first quarter of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2024, driven by a combination of increased patient demand and the timing of large government orders in all regions</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The increase was partially offset by lower KUVAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> product revenues attributed to continued generic competition as a result of the loss of market exclusivity. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">GAAP Net Income</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> increased by $97 million to $186 million in the first quarter of 2025 compared to the same period in 2024, an increase of 109%, </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">primarily attributed to higher gross profit driven by the factors noted above. The increase was also attributed to lower operating expenses following the termination of certain early stage development programs following the company&#8217;s 2024 strategic portfolio review and focused ROCTAVIAN strategy announced in<font id="i4fd32d66516b4bac8d79d67486b5ec0f_40457"></font> the second half of 2024. These increases were partially offset by higher tax provision primarily due to increase in taxable income. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Non-GAAP Income</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> increased by $81 million to $221 million in the first quarter of 2025 compared to the same period in 2024, representing 58% growth</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The increase in Non-GAAP Income was primarily due to the factors noted above.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">First Quarter 2025 Business Highlights</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Innovation</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Skeletal Conditions&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In March 2025, BioMarin presented new data demonstrating favorable safety and strong adherence in real-world clinical practice with VOXZOGO in children with achondroplasia under the age of 3 years old at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Meeting. No treatment-related adverse events nor any dose interruptions were reported among 63 children followed for up to 23.7 months. These real-world findings further validate VOXZOGO's established safety profile and reinforce the therapeutic benefit seen in clinical studies. The study's safety results, including in infants as young as 1 month old, add to the growing body of evidence supporting early treatment initiation with VOXZOGO, consistent with new international treatment guidelines published in the journal </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Nature Reviews Endocrinology</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> earlier this year.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In April 2025, BioMarin completed enrollment in its pivotal Phase 3 study with VOXZOGO in hypochondroplasia and the company is on track to share topline data in 2026, with a potential launch in 2027. BioMarin plans to leverage its multiyear track record treating children with achondroplasia, a related condition, to raise awareness and treat children with hypochondroplasia across the globe. The CANOPY clinical program is continuing to advance VOXZOGO in additional new indications, including idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">With BMN 333, BioMarin&#8217;s long-acting C-type natriuretic peptide (CNP), the company enrolled multiple cohorts of healthy volunteers in its first-in-human study, with initial pharmacokinetic (PK) data expected by year-end. Detailed data from this study is expected to be presented at a scientific forum in the first half of 2026. Pre-clinical data with BMN 333 demonstrated sustained 100 pM concentrations for free CNP, representing an approximate 2-3 fold increase versus published data in an analogous pre-clinical model for other long-acting CNP analogs.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Additionally, BioMarin recently met with FDA and reached agreement on an overall clinical development plan for BMN 333 in achondroplasia. Assuming the Phase 1 data are supportive, the company plans to initiate a registration-enabling study in 2026, supporting a previously disclosed target for 2030 approval. BioMarin plans to seek similar agreements with additional global regulators in the coming months.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The company announced in April that its pivotal study with PALYNZIQ for the treatment of adolescents between the ages of 12 and 17 met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels. These data will support the planned submission of applications in the second half of 2025 to expand PALYNZIQ age eligibility in the United States and Europe.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Other Clinical Pipeline Programs&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BMN 351, BioMarin&#8217;s next generation oligonucleotide for Duchenne Muscular Dystrophy, and BMN 349, an oral therapeutic for Alpha-1 antitrypsin deficiency (AATD)-associated liver disease, continue to advance. Initial data for BMN 351 is anticipated to be presented at a scientific congress in the second half of 2025 (including muscle dystrophin levels from the 6 mg&#47;kg cohort after 25 weeks of dosing).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">During a recent strategic portfolio assessment of R&#38;D programs, BioMarin determined that the evolving profile for BMN 370, a pre-clinical candidate for the treatment of von Willebrand disease, did not meet its threshold for further development and commercialization. The program has been discontinued and impacted employees have been redeployed within BioMarin.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Total VOXZOGO revenue in the first quarter increased 40% compared to the same period in 2024, representing continued strong global demand since its commercial launch in 2021. As of the end of the quarter, children with achondroplasia in 49 countries around the world were being treated with VOXZOGO.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In the U.S., BioMarin is investing in focused initiatives to drive continued expansion. These efforts include increasing field personnel to broaden the prescriber base and adding awareness platforms to drive adoption of VOXZOGO treatment. This is expected to begin increasing the rate of U.S. expansion in the second half of the year. Outside of the U.S. (OUS), from where the majority of VOXZOGO revenue is generated, uneven ordering patterns, consistent with BioMarin&#8217;s other brands, were observed. This OUS dynamic is expected to result in VOXZOGO full-year revenues being more weighted towards the second half of 2025.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Enzyme Therapies revenues grew 8% in the first quarter Y&#47;Y, driven by strong continued demand for PALYNZIQ. Strong PALYNZIQ performance as well as solid growth from BioMarin&#8217;s other enzyme treatments are expected to continue throughout 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value Commitment</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In the first quarter of 2025, BioMarin delivered strong results across the business. Total revenues for the first quarter grew 15% Y&#47;Y. First quarter GAAP Operating Margin of 30.0% expanded 16.4 percentage points Y&#47;Y while GAAP Diluted EPS of $0.95 increased 107% Y&#47;Y. First quarter Non-GAAP Operating Margin of 35.7% expanded 11.9 percentage points Y&#47;Y while Non-GAAP Diluted EPS of $1.13 increased 59% Y&#47;Y. These measures of profitability increased at rates faster than revenue growth, representing the company&#8217;s focus on operational efficiency. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">During the quarter, BioMarin continued to realize the benefits of cost transformation initiatives implemented in 2024, resulting in a decrease in GAAP and Non-GAAP R&#38;D and SG&#38;A expenses Y&#47;Y. Throughout the remainder of 2025, BioMarin expects to increase investments in VOXZOGO indication expansion, clinical pipeline development, and commercialization initiatives supporting the company&#8217;s Skeletal Conditions and Enzyme Therapies business units.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The company generated operating cash flows totaling $174 million in first quarter 2025, an increase of 271% compared to first quarter 2024. Total cash and investments at the end of the first quarter were approximately $1.8 billion, and with anticipated increasing profitability, BioMarin is positioned to generate increasing operating cash flow into the future.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Today, the company reaffirmed its previously communicated 2025 full-year financial guidance, which reflects the impact of tariffs that have already been enacted but does not reflect the impact of potential future pharmaceutical tariffs. BioMarin has immaterial exposure to U.S. tariffs for China, Mexico and Canada across its global supply chain operations and product sales.</font></div><div style="padding-left:27pt;text-indent:9pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.147%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$745</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$649</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Product Revenues by Product&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">VOXZOGO</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$214</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$153</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Enzyme Therapies&#58;</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIMIZIM</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$188</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$193</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NAGLAZYME</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PALYNZIQ</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALDURAZYME</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRINEURA</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Enzyme Therapies Revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$484</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$449</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">KUVAN</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$25</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$36</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ROCTAVIAN</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$11</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Net Income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$186</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$89</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Income </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$221</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$140</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Operating Margin % </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Operating Margin % </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Diluted Earnings per Share (EPS)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.95</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.46</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Diluted EPS </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.13</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.71</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59%</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents &#38; investments</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,779&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,659&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1)&#160;&#160;&#160;&#160;Refer to Non-GAAP Information beginning on page </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"><a href="#ib1266994b1bd4e69bf80b8ec9b3834e1_13" style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">10</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> of this press release for definitions of Non-GAAP Income, Non-GAAP Operating Margin percentage and Non-GAAP Diluted EPS along with the related reconciliations to the comparable information reported under U.S. GAAP.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;GAAP Operating Margin percentage is defined by the company as GAAP Income from Operations divided by Total Revenues.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Non-GAAP Financial Information </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the company is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews&#59; potential future asset impairments&#59; gains and losses on investments&#59; and other unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors.</font></div><div style="margin-top:10pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">2025 Full-Year Financial Guidance (in millions, except % and EPS amounts)</font></div><div style="margin-bottom:12pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.009%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025 Guidance Reaffirmed</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,100</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,200</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Operating Margin %</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Diluted EPS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)(3)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.20</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.40</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million.</font></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Refer to Non-GAAP Information beginning on page </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib1266994b1bd4e69bf80b8ec9b3834e1_13" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS. </font></div><div style="margin-top:4pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioMarin will host a conference call and webcast to discuss first quarter 2025 financial results today, Thursday, May&#160;1, 2025, at 4&#58;30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at&#160;www.biomarin.com.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.701%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#47;Canada Dial-in Number&#58; 888-596-4144</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Replay Dial-in Number&#58; 800-770-2030</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International Dial-in Number&#58;  646-968-2525</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Replay International Dial-in Number&#58; 609-800-9909</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Conference ID&#58;  4327591</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conference ID&#58; 4327591</font></div></td></tr></table></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About BioMarin</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult to treat genetic conditions. To learn more, please visit www.biomarin.com.&#8239; </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about&#58; future financial performance, including the expectations of Total Revenues, Non-GAAP Operating Margin percentage, Non-GAAP Diluted EPS and Operating Cash Flow for, in certain instances, the full-year 2025 and future periods, as well as profitability growth in 2025, and the underlying drivers of those results, such as the revenue opportunity represented by treatments for Skeletal Conditions, namely VOXZOGO, the expected demand and continued growth of BioMarin&#8217;s Enzyme Therapies portfolio, including PALYNZIQ, and the expectation regarding the full realization of the benefits of BioMarin&#8217;s cost transformation program&#59; plans regarding BioMarin&#8217;s revamped corporate strategy and operating model in 2025 and beyond, including expected growth in the Skeletal Conditions business unit and execution of BioMarin&#8217;s business development strategy, and its anticipated benefits&#59; the timing of orders for commercial products&#59; BioMarin&#8217;s ability to meet product demand&#59; the timing of BioMarin&#8217;s clinical development and commercial prospects, including announcements of data from clinical studies and trials&#59; the clinical development and commercialization of BioMarin&#8217;s product candidates and commercial products, including (i) expected advancements of pipeline candidates, including BMN 333, BMN 349 and BMN 351, the anticipated initial data read-out for BMN 351 in the second half of 2025, the expected data and data presentation for BMN 333 in the first half of 2026 and plans to initiate a registration-enabling study for BMN 333 in 2026, as well as plans to seek similar agreements with additional global regulators in the coming months&#59; (ii) plans to submit applications to expand PALYNZIQ age eligibility for the treatment of adolescents with phenylketonuria between the ages of 12 and 17 in the U.S. and Europe in the second half of 2025&#59; (iii) expected topline data from the pivotal study in hypochondroplasia in 2026 and launch in 2027&#59; (iv) the expectations regarding global expansion of VOXZOGO for achondroplasia and expected increase in the rate of U.S. expansion in the second half of 2025&#59; (v) plans to advance five new VOXZOGO indications with BioMarin&#8217;s CANOPY clinical program&#59; and (vi) plans to reach greater number of patients around the world across BioMarin&#8217;s Enzyme Therapies&#59; the expected benefits and availability of BioMarin&#8217;s commercial products and product candidates&#59; and potential growth opportunities and trends. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others&#58; BioMarin&#8217;s success in the commercialization of its commercial products&#59; impacts of macroeconomic and other external factors on BioMarin&#8217;s operations, such as trade wars and potential future pharmaceutical tariffs&#59; results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials&#59; BioMarin&#8217;s ability to successfully manufacture its commercial products and product candidates&#59; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates&#59; the market for each of these products&#59; actual sales of BioMarin&#8217;s commercial products&#59; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption &#34;Risk Factors&#34; in BioMarin's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated by any subsequent reports. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioMarin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BRINEURA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KUVAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NAGLAZYME</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PALYNZIQ</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ROCTAVIAN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, VIMIZIM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VOXZOGO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ALDURAZYME</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of BioMarin&#47;Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this release are the property of their respective owners.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="ib1266994b1bd4e69bf80b8ec9b3834e1_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025 and 2024 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:20pt;text-align:center"><font><br></font></div><div style="margin-bottom:20pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.950%"><tr><td style="width:1.0%"></td><td style="width:70.448%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">REVENUES&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net product revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734,644&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637,815&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,501&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,018&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745,145&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648,833&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OPERATING EXPENSES&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales </font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,558&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,180&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,731&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,987&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206,116&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225,906&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,847&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,298&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,000)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521,252&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560,371&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCOME FROM OPERATIONS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223,893&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,462&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,013&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,365&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,863)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,547)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,954)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,267&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCOME BEFORE INCOME TAXES</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238,089&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,547&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,403&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,885&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET INCOME</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,686&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,662&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EARNINGS PER SHARE, BASIC</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.97&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.47&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EARNINGS PER SHARE, DILUTED</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.95&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.46&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190,967&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188,866&#160;</font></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,474&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199,262&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="ib1266994b1bd4e69bf80b8ec9b3834e1_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:63.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024 &#8317;&#185;&#8318;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048,803&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942,842&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223,532&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194,864&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">739,177&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660,535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,274,848&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232,653&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,545&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,533&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,467,905&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,232,427&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506,724&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521,238&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,032,613&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,043,041&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247,346&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255,278&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196,199&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,460,566&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,489,366&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235,654&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251,391&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,147,007&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,988,940&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628,213&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">606,988&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628,213&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">606,988&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term convertible debt, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595,650&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595,138&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,685&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,824&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,353,548&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,330,950&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:14.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $0.001 par value&#58; 500,000,000 shares authorized&#59; 191,755,802 and 190,761,349 shares issued and outstanding, respectively</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,794,302&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,802,068&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company common stock held by the Nonqualified Deferred Compensation Plan</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,177)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,227)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,151&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,653&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,009)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194,695)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,793,459&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,657,990&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,147,007&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,988,940&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;December&#160;31, 2024 balances were derived from the audited Consolidated Financial Statements included in the company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2024, filed with the SEC on February&#160;24, 2025.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="ib1266994b1bd4e69bf80b8ec9b3834e1_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BIOMARIN PHARMACEUTICAL INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2025 and 2024 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.694%"><tr><td style="width:1.0%"></td><td style="width:67.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,686&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,662&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,069&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">990&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accretion of discount on investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,362)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,502)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,700&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,249&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,000)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,967&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,429&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized foreign exchange gain</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,026)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,804)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,267)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,590)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,386)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,335)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,820)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,327)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,353)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,624)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,130)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,655)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59,006)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,069&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,309&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174,394&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,971&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,768)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,104)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturities and sales of investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,804&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,533&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(89,274)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(121,665)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of nonfinancial assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,000)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28,238)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,236)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercises of awards under equity incentive plans</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,197&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,779)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49,948)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,779)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42,793)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,416)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,927&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,961&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,131)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beginning of period</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942,842&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">755,127&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">End of period</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048,803&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746,996&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="ib1266994b1bd4e69bf80b8ec9b3834e1_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Information</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results presented in this press release include both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP R&#38;D expenses and Non-GAAP SG&#38;A expenses are defined by the company as GAAP R&#38;D expenses and GAAP SG&#38;A expenses, respectively, excluding stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. Non-GAAP Operating Margin </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percentage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is defined by the company as GAAP Income from Operations, excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, divided by GAAP Total Revenues. Non-GAAP Diluted EPS is defined by the company as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under the company&#8217;s equity plans and convertible debt in periods when they are dilutive under Non-GAAP. The company&#8217;s </font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">presentation of percentage ch</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anges in total revenues at Constant Currency rates, which is computed using current period local currency sales at the prior period&#8217;s foreign exchange rates, is also a Non-GAAP financial measure. This measure provides information about growth (or declines) in the company&#8217;s total revenue as if foreign currency exchange rates had not changed between the prior period and the current period.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities&#58; the discovery, development, manufacture, marketing and sale of innovative biologic therapies. Because Non-GAAP Income, Non-GAAP R&#38;D expenses, Non-GAAP SG&#38;A expenses, Non-GAAP Operating Margin </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">percentage,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Non-GAAP Diluted EPS, Non-GAAP Weighted-Average Diluted Shares Outstanding and Constant Currency are important internal measurements for BioMarin, the company believes that providing this information in conjunction with BioMarin&#8217;s GAAP information enhances investors&#8217; and analysts&#8217; ability to meaningfully compare the company&#8217;s results from period to period and to its forward-looking guidance, and to identify operating trends in the company&#8217;s principal business. BioMarin also uses Non-GAAP Income internally to understand, manage and evaluate its business and to make operating decisions, and compensation of executives is based in part on this measure.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the company&#8217;s results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its Non-GAAP financial measures&#59; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the reconciliation of GAAP reported to Non-GAAP adjusted financial information&#58;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reconciliation of GAAP Reported Information to Non-GAAP Information </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(In millions of U.S. dollars, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited) </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.678%"><tr><td style="width:1.0%"></td><td style="width:75.740%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Reported Net Income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">186</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">89</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense - COS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense - R&#38;D</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense - SG&#38;A</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and restructuring costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (3)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on investments </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax effect of adjustments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.126%"><tr><td style="width:1.0%"></td><td style="width:52.006%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.703%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dollar</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dollar</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Change in Total Revenues</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustment for unfavorable impact of foreign currency exchange rates on product sales denominated in currencies other than U.S. dollars</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP change in Total Revenues at Constant Currency</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.971%"><tr><td style="width:1.0%"></td><td style="width:58.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.584%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">R&#38;D</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SG&#38;A</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">R&#38;D</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SG&#38;A</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">159</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">206</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">205</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">226</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and restructuring costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (3)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP expenses</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.545%"><tr><td style="width:1.0%"></td><td style="width:63.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.773%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of GAAP Total Revenue</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of GAAP Total Revenue</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Income from Operations</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">224</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30.0</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13.6</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and restructuring costs </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Income from Operations</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.7&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.8&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:3pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.540%"><tr><td style="width:1.0%"></td><td style="width:76.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.996%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Diluted EPS</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.95</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.46</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of nonfinancial assets </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance and restructuring costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (3)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on investments</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax effect of adjustments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Diluted EPS </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.13&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.71&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-27pt"><font><br></font></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Certain amounts may not sum or recalculate due to rounding.</font></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) &#160;&#160;&#160;&#160;Represents a payment triggered by a third party's attainment of a regulatory approval milestone related to previously sold intangible assets.</font></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;These amounts were included in SG&#38;A and represent severance and restructuring costs related to the Company's 2024 corporate initiatives and the associated organizational redesign efforts.</font></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Represents an impairment loss on non-marketable equity securities recorded in Other income (expense), net.</font></div><div style="margin-top:3pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Non-GAAP Weighted-Average Diluted Shares Outstanding were 196.5 million and 199.3 million shares for the three months ended March 31, 2025 and 2024, respectively, which were equal to the respective GAAP Weighted-Average Diluted Shares Outstanding in the periods presented.</font></div><div style="margin-bottom:12pt;margin-top:15pt;padding-left:13.5pt;padding-right:13.5pt;text-align:center;text-indent:-27pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>bmrn-20250501.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ed8860d5-ee22-4abf-911e-4fd9712009c9,g:31fbccfc-c739-4858-a702-763c43964974-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bmrn="http://www.biomarin.com/20250501" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biomarin.com/20250501">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20250501_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bmrn-20250501_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.biomarin.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>bmrn-20250501_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ed8860d5-ee22-4abf-911e-4fd9712009c9,g:31fbccfc-c739-4858-a702-763c43964974-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1b6421cd-4f6c-4983-8618-1cfd8098efdd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_36b33539-96ba-4e8f-84bd-b4eb6643babb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cab29f35-e27c-4fb8-83ea-5b254e7261e3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_68212f7c-9433-4604-a7ff-b30fdc1dc5bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_be11147e-408d-48ed-8071-f5b438567ba4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_8096bf4a-edfc-4621-abc7-904edc6d25f5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d9843285-9bc6-459f-8326-edfda921e637_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1d5a6fcb-9132-46cc-a8c4-cc7a15577367_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_153cffdb-705f-43c2-a4c9-0cea02ce32bb_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bbd48500-7e4a-4917-bb32-2c7ab605ad02_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_e4343048-461c-4a08-a718-f40b57afdd39_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_4fab1473-826f-4d88-9f71-072d53b089e3_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c16b9000-6c3b-4fa6-9822-2bf546916e09_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_18c161cc-c86f-4add-89e0-10b06b0937cc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1a2d08df-be6d-45d1-bb30-f21469e4315a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_34fb82cf-bace-4e9a-8795-990f8168eec8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f26dd01e-261a-494e-b0b3-7e876c257c39_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f6e23324-3f69-4229-b4f6-657ab6d5c009_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_886b4e83-91b7-4fc2-8683-62415b64fbe5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c98a5ec4-a6b3-410e-aff8-c1f477948b48_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ef7b4848-0658-4805-9375-f50ac51e022c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_16abe783-fcdc-44c2-a7c9-f0b32313e9c8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1bfeb8a3-9f88-47d5-8fca-b1e165fd64e9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>bmrn-20250501_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ed8860d5-ee22-4abf-911e-4fd9712009c9,g:31fbccfc-c739-4858-a702-763c43964974-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biomarin.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="bmrn-20250501.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.biomarin.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fa3d544c-d33f-441f-86aa-baa38ee2a65e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_DocumentType_fa3d544c-d33f-441f-86aa-baa38ee2a65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4bb54be3-6f9e-4281-ab52-4afabe6fd75a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_DocumentPeriodEndDate_4bb54be3-6f9e-4281-ab52-4afabe6fd75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8aac9ab0-6b60-4633-aa9a-d8c646048109" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityRegistrantName_8aac9ab0-6b60-4633-aa9a-d8c646048109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_369b41a6-eaf0-4520-9010-3fd5f93b45c9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_369b41a6-eaf0-4520-9010-3fd5f93b45c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6b954a4a-6569-44b6-915b-5bf4dbab4500" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityFileNumber_6b954a4a-6569-44b6-915b-5bf4dbab4500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ddecebf8-7d22-4e17-8d11-01ee4af07042" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityTaxIdentificationNumber_ddecebf8-7d22-4e17-8d11-01ee4af07042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_23f5b26f-e3e2-4681-8610-9b9c1b2b1a7a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityAddressAddressLine1_23f5b26f-e3e2-4681-8610-9b9c1b2b1a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_97ca8417-16cb-4e84-90e5-de55efeff158" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityAddressCityOrTown_97ca8417-16cb-4e84-90e5-de55efeff158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_26f30863-d3ab-4e1a-a40b-24c6a3374662" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityAddressStateOrProvince_26f30863-d3ab-4e1a-a40b-24c6a3374662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_62db01ac-2e74-413e-b092-57a9aff6368e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityAddressPostalZipCode_62db01ac-2e74-413e-b092-57a9aff6368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4ec3c0a4-d127-4f55-987f-29e8471a5208" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_CityAreaCode_4ec3c0a4-d127-4f55-987f-29e8471a5208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_43ce9b04-62a0-4e6c-ad6c-5fb2b6ff7b0e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_LocalPhoneNumber_43ce9b04-62a0-4e6c-ad6c-5fb2b6ff7b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_0f9cfb78-f1b8-4959-adc8-91187b855055" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_WrittenCommunications_0f9cfb78-f1b8-4959-adc8-91187b855055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_efa9fe29-1526-4e00-b4e6-735c2807376f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_SolicitingMaterial_efa9fe29-1526-4e00-b4e6-735c2807376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_418797ef-d0f1-4774-909e-70067c19bca1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_PreCommencementTenderOffer_418797ef-d0f1-4774-909e-70067c19bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_1ee4edda-f8f5-49a4-9595-711317dec9ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_1ee4edda-f8f5-49a4-9595-711317dec9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c0687aef-6870-4f5d-8ba8-6263f19b9e17" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_Security12bTitle_c0687aef-6870-4f5d-8ba8-6263f19b9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_07b04c9a-2274-4905-a3be-7a7b78ab489c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_TradingSymbol_07b04c9a-2274-4905-a3be-7a7b78ab489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0b79f7c3-9081-4bec-a4ef-3f040a4711f0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_SecurityExchangeName_0b79f7c3-9081-4bec-a4ef-3f040a4711f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b3527978-d717-44a3-b6da-037a7b8128e8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityEmergingGrowthCompany_b3527978-d717-44a3-b6da-037a7b8128e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_22a316d4-bafa-48bc-962b-a83a937b25d6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_AmendmentFlag_22a316d4-bafa-48bc-962b-a83a937b25d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ba876ccb-c379-43a5-be4a-2f35882bec1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1c76136b-bcd4-4697-94bb-e400ca56faa7" xlink:to="loc_dei_EntityCentralIndexKey_ba876ccb-c379-43a5-be4a-2f35882bec1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
MB5!.1PT*&@H    -24A$4@  !=P   #>" (   "HIU6?   @ $E$051X >Q]
M"7Q4Y=7^S61GWZT;@A! M-KEWZJ09/:9!+2VVD4A"XN[U@549%]"R#+90Q)
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MA*(N1$=(//ST1V>X%LY=]P=XAT,JZ9=0@8F=3^<?*"W-B_7__SE:H$?OQ-[
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M+U1Y26A&GFIR+G'T,19W$-C9R\WV&[K,F@&QM>KS]61?^+8)<UNC#H4[S 9
M1MN@CK#Q5B&:A6BA%VWFP..WK61+\H!\-RQV"/&Q$+O(K#,S_?9I$8WP$T6(
M[]_VDU'3ED[)*7KBWWH(%B*WF*$K&H(5>F6??MA>-V0/!&6HV9FE%:7U!_X=
MHN_O#T7#0K3* !"/7 KM)L"QDZU)AF+@-.2J6L24B24]H-^S&*6Q[+'H_%C
M!H\+"G$B(\(2*SB'"3$L<V)?$9HTVGE+[]E.<=Q\VL77G^N[TY57^?U;[\M;
M^/.K;G_@REL?N.KV!ZZZ]8&K;MTRZY8'9MW28\_'CWQ/7]]RU:VQ[<K;MEQY
MVY8)TV^:E'W+C#FU^0M_]KWK-LR[^U=%32^MV_C<GUYJ^_<.O5V%Q.^B0'?X
MQWD$F,:9,0FYPRR$(NY3ZV5,#T)6RQ,"E*%GBY7-PS#M%FJ[T':(T/OJFX_O
M^$W5?XJO>^V6W+=NF/;>W/-V%9Z[>_:DMOS)>^9,:2N<M"-OW(Z\<;OF3.2M
MN>#L7?D3=Q=,VC4[H_6JB?ORSMGS@TG=^5_;?M64C^9\M>6FB_Y9\+67?NQI
M^^4ZT?F>B+1"8[2P,,IGTB\'#R-*K;&(%T;:-N@@\<<-E819J09W+*H14BE$
M6U \\MS[=U7^UCVWY)2LFX=FWCG<LR[569[@J$[.:9)\M=*,]=+,>LE;F7AI
MH^2KE+SEDB\@^2HD;[G-7R$YBY/\ <E3G.0M2?15 &WQU?3<JG#07XW-'<"6
M4Y.06ROYZ61G(-%5;7-6I?G72ZXJFZ=&<E8F>FL3W-4V7S7>NBMPW%>=Y*M+
M\98/R%YRAG]9YMRJ.VK^^)=_M742,R-J(JVQF1L3KR9& P'/.5 ,4(8A[P,
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M4%:99U[C]KTT*=6@(@>I\ 6_U3A9[)%>O/^\P[4 @S+0 +#V<Q0G@S+4X*0
MZ!KRR(0I>FY<]M5#7$N/7 H-=*\XU7Y;R7U/("J-M0D*CB'=@TP%MA=8TS"M
M^$@(AB_L)'8Q09,57:IX9W?T@:??6_[ WU=L>6W%IE>*&I^N_\4KC_R[<ZO)
MQT&B:!;PH,T@+CM*"6PE6%"]:#ND29;@K4KP5MD\L2T)LAAO^:,CW%M7B#_?
MLOWB#_*9DJLBT1T8X*L8ZBL;E+EL^$4+S\E=YB\,E-SSU+-O[.>@RH@92X8P
M:ZK^AMZ)=(,4J8?5:">%N))P)]39$.W<J8<;B+W[<X!1@O+OT$-I(KI/;'OY
MK=J;7[_5\7K>I \*)[=>]]5MA9-WYDW9EW_>GA\!CFG/IWW>Y#VSI^R9/=7<
MSN,7[7G 9?B</?GC]A2<UCKGM*WS,CZ8/_6_\Z=NFSNYI7!\<V'&NX5?>_>N
M'XEG'Q,=^X4FP@A]E:DR8K]>_FE#QB@ZCLH9*J(PXP:AHB) CR.MV6L4%F)G
M2-SSAW_DW]UXMN?&,=FW#K$O3K.O&@!.2IWD:9"\39*W0?+62]XZ<^[TQ%],
MI";!4T^GQ>^-+QK0#&$W>/T)("9V!.?$(S[\&K]^B*U&0IQ4J>0-).96)W@"
M4N::U*SEHUU+Q[L7%MQYW^^?^G!/!$DN +(8B2K"0H0T/1*-AKE]4&E;B>I:
M5-7"I*C!\$"S<>CIIS7V2?39@: ,,6(>_T?+H.REDKLF\=+UDJ\\Q5LZPG''
M_7]X-4*?POV@BT@DH@HY;.2W[P\'.[''#'%DJ-:2K*#>)%8-783":EB(O[VU
MY^Q+5PWR!R17M>2IDQSEPQPK&)0QO$F8= 3*D(RW2!]&D[&J=&*WW^=^.G.>
M,CI#NJQY38XJY 6"_8 13>S7Q:K-?QOD7I?HV9#DK$MW(3O[MPIK=Q-9(QP$
MW0E5#ZCQJ19I__IK-N@Q^%]#M50J\\RC'5H\&08*A81<L>!7([)6#W2M2?44
M)7L"".S% MJK5/KC>C/UDK])\F^4?+21-I+@J;=YZI+<-8G.BF0GD(+![K+!
MGI*AGG4CO&O3I]TY^?*2J\O^=/]?MFX+B7VJ"%*E2+0J9:]&" K^-$U$HVI0
MEB.&2Y6.JO3'9YR(>XLBAT'&' 36$%5"55;?__<1]KO3W"7)WNH4>T6ZJY;B
MP=0  "  241!5#H)]E<-5#M/0X*GP>:N3W;76%N:IW*0:\TI]@4M)P8H0U!
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M*A;!UPM&SE'<@C5WC>66=15S]>T'90X-RM1)[D;)49=PZ3W2C ;)49F:6S_
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M@Y_KRCSU99[&T9Z&4:[&$G=CB;NY5&HM]L68-\$":Q$AE^+@%/@2\"P](!V
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MUXXN7S'*U^GPKR81.^1+4Q%WX6KHFMR""V-F*@F&,S1TO5%+L M:,\XPD^*
M9IQAYHJ F>F*L)E-)?YHD:^-.>M*@R&'KZ[8NZ*DXI9C@XO.NW5=ZX__\OAK
M_?J28PP406\!+F$<R;T0-X5WH)NSGP<:(?^!7\3>7SP;[VDD.])'3!QD/\G\
M-\\G;XW_P7EE8H)K_BCWXM&>VG'!\-A@W%;9QLI#V&QXJ67<K1 2=K46!3L<
M""$* >,<*)/';1:I-P8T@RBQ>$1! _'$[,$UHP/KB\YI/M&WZK^^U[5A.\U?
ML)I F4G+O5D-]1I&WI ;JB4139_W5Z(7](XQ#$4^**.7[D).F3'JA-R8&)RY
M9XLO8O-%+8$H<[>Q -+N1I]]RUV_>PD9N6G@U,C)SLI9A08_^#)&;G;>Y11>
M'L86 "BC(?0'.04!QZ138/&G./_CR]M/.G?%F$ +X%VI@[F0,RCP7\,$D?X%
M.;5[(S+,GR@ME,0>]KZDV8K4(9689Y0/2T88,.>\[D?'^NOL@1#SM#%/S :"
M(:;MH/2E("HK6X!*QT ?\*YV^+O&.%?-NKAE<P;]KG$UE>GG/*MJ256E>O:F
M +!IMW7#7D!4#[*##QJ4T?-P(09G^)RDEN)/.()=-G=KB;M^Q@6)6]<_MWS]
M7U>L_?.J$>:B#W&S\$S=G<^O6/OL=4U__,:-/_[ZC7>?O^!7SLN__YG*%9-G
MK9Q843O163?>W5CF:1SE;1SE:RKVMZ"8@(2*!\S90IDF>XGL$*F3%G=4 ' 0
M@QX)VHBVBF)5"6A'!M<S=VR<J_:TZL5_?GEW'^D.9%1%5A59SI FJ"K+&2@P
M'CT_AC]ED-V$LX)GS-L"*),/RI0YZZ'=@:1XJ!.2H"%QJV$>P:X2K@X(H>ZH
MS1,=)S6?$%CRX#_2/1I1Q<$&SZ8R26Q2@(E3&8]DZA/@(!Z6\7ZH0!FD+ZU_
MQDA?0B!0]]C17?#F$6/0%&C*K']V6L72B>4W//P6Z:EED:\@I_%XX(G-8]P+
MQGANV@4D)Z5P)*U=6?>SR6=]SW5^^/W=]'G.4TD%6R3*S4]Q_IV5OQQ=T6CU
MK!D:4P:B#.[Z"=Z%OWQR\X#&!V2<O9?S'I%5Q7F*TF]Z2!@"BM/@:8VXAR@J
MOL=S/^>[LGA CX?S#_KX(\]NNNO>IZ^O_Y'[DN:IY=\M_>KW1KM7E0;#4+\#
M.R9:/'L-*V]EE6UV40C&&V>NB"@ 3- ,[8&-8N%BBAIYO%!+95*G58J/<H8F
MSEJR8O6CO317A11%?V9 R#Y1CC8Y,N9V]!#OZO0=EFF>]=\QT0;!!,:F&JB'
MEN39[7S@K<WKECYUY<Q-5WUY\W]_KO=;Q_5?<L+.RTYZ_Z(3WK_XI*U7GK'[
MLC.V731]J*#,!Q>=LFGN]*V73O_PDE,WS9VQY>(9VR\\8]>W9NSZUBF9:\[8
M-O>X-R\X=L.W__WQR\_>^=-FGGR'JS!Z&L]2Y@@VQ)A)YFY^,"AS6,S'D+Y$
M):@%Y)=<:XNN%S%H5>89E%CC2D91L@.9;(9FW\^?Z3NA>M485TNI)U'DZK!4
MM@-? -V#UHE<=2'0$_2A2#GGIJ8F0J/(;Z*21IZ8X'_9@^TEU1W,';)(<7S
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MJ$BWE[G6*\-[WZCREKN?.WG.BG'NY27>)KLWAA(<Q(Z!78*9$L+)T.BQ0IJ
MA$+\(=32KFYGGN:2FKC%U<0JFVS^CM&^AIKKHCNR=#TBQQH)_AE-I?0]VC(9
MZ$S>FC5B1J_9^P509M]]0J!,ANM,&5!C]/ 2K5P8,")T1Z ,/)P8\X01,44E
MNPXF(2W4$@@[I*;Q[KKC7+?]YNG=_92+K7)DFJ0!R^@_QB(KG!RQ\C8!53T
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M0<F&!K H\D)S&+)/<1: $!20&G?,*L6!R/A:6774/J>]N&+9=2V_$Z$, AQ
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MV#YKZ;&>VW[UQ-8,2;ASKF9DE'D6R;$??;E']EW=\1+#$,^4U:)DN)S"0^A
MBU07E'3/8N%*]_%4#T_M)HQF*Y@UF0]Y9C//;N'R)CRRXK&9CN_F2C^2]&@;
M-C@-Q,Q!.[)M<,!OS^U=]_HHW@+&).!-5<ZF>FEMY[M2X,@D[G]]FG/>.-<2
M^ZRE-F>3U=]NK^JB'')4Q\@KD"$R:P@!1&E,I"\AZU7XUE*"N6/VFC7,VUY:
MU5[J:9@JK3C1MZ#][N<VIVD8]\%7([EK/'^"?P3R!<2=?@3TWJOQ'LY?V\IK
MUSQVJF]E\9<7C/)$F0NJEDP*68+-S+F,>9N*@G%6'BN=\S]PR_3P"#S@/&J
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MQMT*O__OVZ<X;[8[ZY@[9O&M1AC3%4,E9G\'TT$!JEF#.@NF[JP0U#1$R/2
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M@#+#TE>TUBHH4JNHT.F$K<-^*,F1M=Q'A9GPZM'7^,F^V@FNYF(W:E:BIFJ
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M[FJ:X%YU^<J?]9!?R%4MFQP PP/<R)'VDP-?]"L3(XK\-G$$!X8#E!FD2V)
M,T)N1C2L58J4!N)V+W+! (?Y(@Y?P_%52Q]^A1I.@UHSIPDF*YJ<(5&J3]F
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MYVE52VH\.Y !>)?5(/4RH/'F]4].JKRU+ # Q5X=8Y[F/$'9;N9+4%2SA04
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MD*\HWOS0M,%A7H!^JEMB([DDPC^10W)T2? <A*8-C*#.ICQLQY]Z%Y<L*+,
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M08P/7,:LS.!,, ?*6.3')$XAA_]0I^#5)BC3!&6.;=C.+6I8V+"/$DM75*]
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M17_-;8^M[Q[P=Z?=H32.A;V4/]22KE#"$\PBC0]Y5U0MT:E2&$#],Z\  "
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M!0,FG&?!P=5R_\=B7Z*R&JI0/Q&&7'/@B].6SFEI[CHNG#!0!J05G.!$K-N
M*6VL-5#.V_NEQU9W;EFE)MQ2$O-N\[4L5&!*QM^3]2BC_IXLSJ5*'F?(<(E
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MR.NKFA-,!<7,YH^:JEB@R:2PKZM">-@E8TRY_"GF;H>2I:=CJF?UD\\1/Z=
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ME#DE-UC$JR$<^14?2LK6 I&$^@<@]6*&%R 7_]2+?(9G19T<J@KT,*F+B*O
MON%^+69G\M!T!CI1I0[SQ%[6V%X7Z'2X6S[PJ<C_9BB#,W@A9V[=Y7@%E'E%
M\[\#?CUIH=_QTB8!R@P7!J4P.X0+BIAO*=.92PN,?8,7^O/\6)%?U77/;'F5
MN;6OT"Z+%PJ#5;ZH4R%0!IUS&_ :42*JA%V*< <CD74IX92B-8U;)C<LO_:7
MSQXK$G.'OBB7!R(#3H'!M5P>$Y"6'6$^\);=P0HH4[ZK^2X#94H+;QHX).Q*
ML+$X+I8W E@4N)V@R>2-0H'6S'H:U?CI G_H,*]7EE<WKF-RAZNIFWDATHE,
M6A2F6D*,Q#"'FC(0]Z9NNS=1ZPW/]*QZ_"\\ ]S49$R\97W_C;[(P/YM4>.%
MW)&''_W99[YQP[\&?_YAWZ__S]([/JS<^U'_0^^1'YS3\,3[@H_/5YZ8[=TU
M5]US>O"I>OG1:8MVS/;NF>_;-5?9/5<1$K^[9KGWUGOVS266#8 8[X'Y\M/S
MY=VG^??-57=/]^R=YCTT1ST\+WAX7F#_3.G@@L"3\Y1?OE_][K\&^+,O\/3
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M#Q&)(J$T!L'21XK\N2S_L._RF9XU3B5B;]X.TYA 5W5S#W.W,D];%9B2PJ]
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MV\X:$PYO;')3RNX-.7P1)D6J%J^YN/WVHQFZST4=2S1*#S):_F2F@+>B1U=
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M,3E6Y^^8N.B*&QY\,0/Z=YJ28S#8=10N:-0L9J L:T_J>]3K1G@9E;>_/2U
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MYFT(\J!7 YI'PD!K$(N<".<[47;G@B&LB+TQA[=CW.(5VV_=0V49.@:"5?J
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M3"T&$I0!-Q53*2$"/H$(@#0QT;LA\M\/F@(AT,@L0.R()%3$%&Z)85'_$;4
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M]E)<H">X947X0O<5^5\X_\"Y&QR+USL"*:P2 ^"E([TF"6HL#@/TX\>BT:Z
MIDZ;0 F7TC[%<]66ZTG0L2"4 @JY@I'+E_P*\+6F^#168F;]XXF=/I(E()L%
M")F+OJU1$=.O_O#2?/_&*D][E1)WP':P$X*I2H0I'::CL*C3))-L@I!23.FT
M!5-.=WAJX^K_ON<PR#(6W^"$3^8?Z8T54.84W$UA3"&Z=R:7I=6F8>2U8MZ
MV@R5KZ[=_L"DA9>XW.NA*M 8@VJ;4!L0;".X'X*19*D@"9E(**P+4,85B(^7
M-\^3+GODD(GY")SU%:E::7"?@JLZ=1]1=E84V,5)XQ&_5D"9MP"4(::DR:0V
MIP#$4F&C8G)#ROJ2#HN (D1_^SG_T0-_G;[XDBG*YCHE2C&?X'@K/Z%^*RJ8
ML%5L*7D)Z9E$==,VMBA4O319'0C5-:SYS]4WOE0P5SBZKI>H,="D&%[*=.IZ
MWX@^J0+*O-M!&7/'#X-$C$L$*:T()U& E\=SH.D>T?E]>W(?6+)RDK02JDN-
M+<P;=S9OLPL) &O#2N1))E-73=I5F&3#=* Y#N=(-52[>.V'EV[<^1R((/@>
M@CQT0RL!EB/JO*/[9D1Q 8L0"D.Q(T>XC)'/<=T #2ZGI8M"74W/YX3KFI7*
M4ZP7$?]U'P4=1MR!4JY7DERFQA'YGWAQ5*^W]$5"J%_45:%38+8W"D5^^U.Y
M"8N6U\DA)D7L@013X@*4P9JY#)2Q*S&'0G9T:HIY$Y/\G?_G<]%!"P L38U#
M5V3-BU8KF2GO&-QL&=7V_P?X<'-"1;_5"US7*8"@^^C4Q0NFDO6^%WC=HF6F
M3AN8,MWT8S(RL#T.FDQO&5(39FJR1FX[0UWV[ #0810QP3873HHT2$6?@3R3
M:;4XU+U&U*YB\);]B?DY0\=Q8.R",D1S%>>,FV$:E&ID0H34,YW.$_WUY2R_
MM.V6V?(JQ]DKQREMX_Q1N]2!)25(CF2)*CS4:"5)-=O8Y[?)\:JF;IL_#K=L
M%&ATNWP]$^3HQ+.N"%[4M>\(]".S!+ER8.X9G3P.!-%OD/-M-^^<V;BRNJ$%
MK.,E*>;O8%)K[=*M;&$[DZ+.8)?X(DJP2OHR$(QW!,+,W<J\R6K_=;:%75/5
MK1,7KF[^]O:#QS WH50!J+A6S*>I/[R2<5E*^\KNZXD\M2(YM6>%*7,B3?9W
MWB/F%U(>HH85T*%H8[A!:SHO#'+>>_NA"8N60_O9U\D" &7L2LPEQT@@@&@F
M_A0J'P,H6B&P!F]@:J)&;OE TZIG^GB_*%FB:47'Q"5DOP&N"5!&\.Q. I01
M7H%@?N$R\ 4%@Q_5>? [U[D6;G!(G79_-[%CPDP-,[F#)%0CEEH'04L0G2$#
M2CEADZ-3E<U-%Z;Z.;()Y OOTG\54.84W'@!RE#6),87ZDD+.N: 8SI_-L._
MLNFFJ>[EM9X-XYM2=LBF=EF@#-5_ 9$Q?RR9R!05$0M0!H0U)H4F2FNNC-]*
M@JD8#?FL!@8Y)8E6_F;V8S,9. 57=FH^8FA6%)FY.#^*$A501C3Q*)<OF>"+
M>3NM3E/ZZK(#9@=&\5U1+Q: RQPS4/5<[[VJ=O&Z:BE&5:NF(K5 $LVTP2<8
M7@)8M/2 O7$GQ.GB3 FA^$[:^*V.6_IH GB%OF\%E+%&\:D9=*_^%&92[\IA
ME[___-UEB6V"Q&9,'0I:F",U#;6I.=* .,[Y?]^U[T/!*R9*:UQ*6Y6*+2!L
M!_EZF#O.E*13-JN6!$A)."61=95.",K('8XE"0@'R"TS RWKK_X]BGX'D2QI
M<.'04#E8)$&^5]_#M_&(U2""MB+0"9(/)-0BS7E?@0^B9"EO1OFAK&HHX)O3
M%65PPY_CR@B6*F6*)H?;"DXZ:0";*PPA-CR:$YV5-)MKN1*?$*>N81\S=N/!
M">XUU9[-R#7]<:9VVI1NJM@,FZ",#VPI <J 1NCO9E+G!#GZU4UWT2R.MBI]
M[%#VP$L[F>;69>E,1O-RW\:.]0_]U>B] I2!K9@@?F5I7ZV0)<$1G?<7^6GG
M;'&8*>"K0!ELUG670!F2_@4H4RVW3S_KHH</%_I06LGSJ,4A4 95?FA2LI\'
M#Q:_68-HA&W]JK61^3E#QW%@K((RPZY;W B 5AKLR NYTK#2=1",LIQ_K?7F
M68%-SC.OJO:TN>2$ _;#7?"5A)2/I=2@4GY#NT_,&V9RV!7L8IY(E9IDC6'F
MZ7#)D0F^Z(1%*_P7=1_N!TJ2T0R2^\%*.Y_7LSH_7N3=-Q^<Z;UJ8K#%X0_9
M U'F";/&SJJF[U*E4KQV28(UKG<J88N-'"-@#ED7DJWF&/-U,%\7D[IJO(DI
M#>M\7XL^WX?I"=6=!MEOB>A;)!D%%& *]SJ1"(K;-Q2?3ZQ76']%?: "RIQ8
MH[WNNZQI#GP3&KFDN6L*0>EP\>+Z7_-\X7GA:6J'H[F;*3&!O#CE1+64K/:F
MG!*%!2'^#5 &-4U.)>Q4H/M;*V_^9LN-8.!RGM;S''T0X*WU=6*VQ1J5%JKH
M'G3H=4_X52]@LPHY"^<PG4%%KZ9IN33G5]_]Q^G*%N9),K77'@PSWQ:<FR\N
M^C- F0"ZL5V-D*]<DOFO9I[.NG-[ZJ3U\QN7/; S@U-!@=6[\U\%E#DU]QT;
M:4:.W(4UKN?T/++J(SI_X!F^\/SNNL95M4JH)@ TD"UJJPX2348$6,S%* _$
M#WP;4!M(6VX4@4U-GPA3VN>?V_*G?HP;;3"']%4WRX=I!K9,#R&X-.;^B9G<
M/$\34Q49.>)\A2DCDH?1+%\JY\+0W%JZ)717*""+B5LCZ0:>$_O<R&&P<D@7
M^661>V8TKJGU1@!M*[V$*I(*$CB5":PX (LG0*ZDRB:13CC\">;N<"Z]AGFQ
M&IW@;YOJ7IZZ:<_+&;.7YL%4Q+\QH/)K;E]7-&6&--C&2^M^\>B+"#?X5TKC
M*-Q0]B\8!'A1="GQQG?JH\@[Z>S+1DBQB+ Z:( VMOME_LW6G\\X\\(9TMHJ
M*00C9*D=>U-R@LDIYM_&Y"ZGG*2]+*$F(YP@J4G5E"W8S:2PW1^Q!4).:?7B
M"WI?YI37@"3"=5WP'S52B32'YEAI2ZM!\@)2%4FEL!/</_BW;;\ZN/$&?N<>
MB&=F2/$L1])__506?X3SXU1HD35MK+"_WT]',G1$!)\L_2WLINEO!^DQ3;\2
MGWFHBY4*+D>M=<2:S9JT2)=!S%ETX?D"7];[R"1?J].]T26<)DB-%3 <F#)0
M7F0^3.2DTMK!U Y[L-?FB4Y:O"'T_:<S!62Q-':P3!+"'U;-5P64&;6;^A9_
ML#ED!"AC,F5$S]4$309^G1@*39?_L%:B F"H-I;J5F+4D0B4 2X#Q6A32X)
MF1F>*V]YXO@Q6F;1&D;C6A9:3M1KZ8O,W1@<.)EP4A8/1=.9(W#H. Z,85"&
MKAN-@-.GPD,BCV@%/:L7L*9$D2B.:T81-C=?;[VM7EX]R;.Y5HH[E"[F3;'
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MBWRB.-?CNJXF.?\\Q;M__^98SXV%<KW5T\A< :;$K).[H=[E%8Q^HP0>C06
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MV78FO>NK7^<A/@$L/TKQ(U(,PK,&(*RB=Z8UTL@3I.!$FC^T\=/Q%:25(P<
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MSN6;/^/QS$)WV.YX/U#&U)2AY(6TQB^^]I9B=P!,&:F%R6$P94"6&0!E++X
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M/U -'$J30PG8_#0V/6U,:2\ZO<MRVDT_F%S??,>../4A(<J11K"A7TOM!<\
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M)",()<8LD_GB8WJ0YOP+C;^5Y./=U]K+5A6<WL9\(5858DHCUM)*.^$R793
M E &N(Q0\2-0QND)3/"L7/?;/\;)^Z#PB,IUD58,!,K0.,@T[G%\,'A0!CU$
MN,$#<41@-.2CHKH%::R @=6)#D-N[0@!9?#0#1'K /-3F5>H\E%,'E+6,42Y
M*@-@C?E0;\0.1SH3&S:'1F:U\J4#D(.D>E9>4WCZ.B:W  =TK1FEK!DCK3A9
M6E4Q=_WO7^X7D@) );043\<)GC#ZC2&9?QSWHL-<>L88Y$"90[74<0[*P(R@
MLB?G??W(8$IR_GF2O[F75UQQ2\&IR_+E%B:W,2ELK6ICGJ!%C@C+8$ S-*#$
MBAO>2WF3U==B\\<L<BC/%[9)37F3EO_;&8W/_QE+,?BO7%/3\$/3D,$V1A+%
M DU0YL@S W*@S'[6#?$9,OH&'D^D "&F1="[KQVVWM\.>B$0#:+29'@T1_L@
M>SH16C9BGP%KR*:;,F"47)KYTV$/L**&/@A40JR(U43MBH&S("^)*NF 58O2
MUU%6&<,F>.EB*9Z%X^1YFZ$=(#4YO"'*<FK#I.B).BJC>9X5)[JO^OGC;_4B
MB27#8Q80@^%+921FAAMV.)0Q.L1Y4B;6$GUJ'WR^_B12X1]^+;7VZ7>NN^7.
MGU[6,G[*[2=.?7C"14^67/14\;3GG!>_R"[9;IV[&:#,K#>=5VQC,S>R:6_E
M72DPEQU&XA+T95X&Q6;.9LN<S1;(QVRV5K]HKWXN;_8?G+.?RYN]R3I[FVWV
M%MO,Y\96W_;#"_B6G1R%N4T2^"$N]ZN>%I;%1'R)<TX$!!W*;Q=>U54B!2S>
MM1:%-,SE ,+@!BB3G=9'H(S4ZO!UL/+&4:YK2%.&8N#XL-S/-[D%A-]#$Y3(
MIS5!&9J?D)&+Y5,"3!F5/[6EIV2(Z4M,#A>[5@9^_GQ<HQ49E==-(U<I"Y0A
MSIVHSC3TMAX 7XSW&K<T<!XGOJV@C,%UI]N/<_ZQRA=$'G>>NK# &[!7M# E
MA J&_G:;%Z6O&4Q$E$WI1+8C6#,QFS>2[VUTGG9]U=5=;^^E(GU<4Y.]E"9J
M5/H8^B,;OG?LASCD-&4.TM"8L,U6RAJ# ^N?S!$=J#JT&U:MWSSJU*4%GJ##
M&['[0U!]%HM/0[$.LXF0<25_(V*7 GE*B)77CZIL^(\SE^[EO >J5,B"U'DJ
MQ?O3T/Q-I+21I4DG!'KW<7YEXX/C)BXIE"*.BD[FH? L_$:2\!-R!A5"JC8,
M?IDK9/6VYE5T6#W1HK*:LHM"GZ7!)D-MJ82*$D^B3J5H]1'F,!VDAPSJU.!
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M@F>:$'G^:2W5Q_E#6W:=Y%J4YVU&_DY5A%4$K>Y0GCMFE<E)0"(/J@08=9=
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M,64(E F3XP1!5_XQYLDR*5NE1)=+.]^YY6,'A6R501$R33QFCOSI/C95@<I
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M$%.&F'^(!4+,%V)*"&>D"),C3(F 4# ;GN5(33!5[8O9W(,N;\CEZ:^2AK#
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MY+$J9:1V[>#REHXK0U\^P!%JD$8D6C $LA%@B,@8%R':;>ER9OI =%KC6?[
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M=7#9<TE[JCP]*_V=^[_R,Z'V)7;3"[F\ ?=)#'?P.R8M,"RET33)K=+<AZZ
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M+R-/BQ?',9/E^3-W/K'M[Z_J:[YRI&G3&"GUIIJW)E;"+TGX+F6 PN!!RC+
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M,--OJ>UKG-_UZ^>7K;ZZ2NZWK;^!N5..8)JD,\62AZ0S29^>S&=): 96)V%
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M%5#&:@\G^-\:U81_F,FGH 421*PG"<(@'N#H-WXYKZ6;N854)]%DA X9,EQ
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M=3#!_)#"JO6%E[JW_NQ/!;24 I4/YYI1,"B3TS3N$>6&XA.!P_&NM7)^]I4
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M.=6<1LWOD KD!=^C0X1(J.F7.J 0W9BM[6>ZTCOF7%EOH(%=W!N>\6L%E*F
M,L<TF2-. $#G_.$B?\NUGU@I[:EK"56W9ID_RM:1"RW,F$A-!BJ_E#.H6+,>
MSL *C07#X,[X$DYW>)G4OVKUQB]\Y\G#*L]C_9,SA,^NJ ;"0ZF%0J>UQ$C
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M,8/3SQ&@C+4G-U-W.O.?6Q9?4[%60)ECRKP"RAQ3)&4GQ)RO@<8Y;O"O_>1
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MH0@&W@R.J *46=%]1X-\X (1&:9D:Z#,TWOT*OP9ND@J__*#)ULZMX&N',U
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M?.DE ZD6I,8M %,3:^0QSE>$;ZV!,F766RU]Z5QV>]IQ&+'&?_PD;^G<5I=
M?4<6FX )RFDGE0J#Z!$.BOAY%IY'!%DP#B45D'=\\AL/GQ^4J7 W3KOL1?@!
M/D1)G<=64=,*!2IX8'!5%8E_UG<5RGU"@0C^O&X4=,S\"YS/J>HQSJ'8!+=)
MYVJ)?L^ W%^I5- AHRN\-/'](CR1N 3Y1E!<I.M;7@ .$BYC\Q6LVQ%I5D:)
M\R\^N/""KJU^:<S1E?$D9JC@L<@ %T*/2%4K:_TB@-,U@K2FGC0+#_LC!Z]]
M7?88Y[.4K411&K25H$=<M">O76BQ6J"@PK*_\SA_T2N3#9&#+#SBHIKH2&)7
MDEBQ(%&)U$6WG*E3\BXIYU(F8392GDD3C3W9D++_SY3^W\QBMZ89>D$4"00)
MAR#/Q;K1LY_GC!%7&046*(D#M?2EL[?>%7;4GH3)!JYF4$908Z!A8?-EBL7B
M@LE_=H*_4!GT1,; >TUDF33&A(AO0F0HH^(2"BRBVEH6":U4DX*%QWT]8[[K
M[KS[OI^#TR&&&!8=! 8K&H=7F#7A<<Z87DY[1L/0D9!2Y/S7)?ZBGOX5RG!]
M5P;T4M2Q@OH 13O@TQ,H0_OMM5,L,N)14IZ>/ NG/%+>%]Z?_N"W3Q&6#4$9
M,7\*WG(-E#FMP2_Q'X0F$:T[-$:H]^!W88R0NTB=K!949!&^;.,]C=U[ZGLF
MF91F4AJZOW(.WX4H#Z 9D&5@0J08@"$)MSS=*(TMBPQ\_#OS)Q"*)_8VKF2!
M,FBC\@B]Q!OLO+=7]1 T#,58P'?\6 -E:J#,><T'@P"5JC5=[-<HF=[@O&A0
M"=DYG;_WTP^O[.IOZ-[?V)-CX8,03+24.B"\3:!,"IM<"Y>!%CX58Z)9/9$'
M+J-,>R+CJV*[7K_CW2=H(3AQ$@71A+RW(.EP DJA*1.I@3)BIXH=:PV4.;_U
M6I^*2? )G?O"_? 8Y D6R\$ZY4P9E(%O$:\"9:(Y")5%Q[V1OD]\_:%+#Y2Q
MW73 ,8 R-<)/YF8!G1H:+Y:0!@BR@,[G%K!P+A2PM\121R]@GF)I5=5B0:]@
M+V+1Q4*+='UJP?*U+JBU%^F7[.6J?'$$1(7D#2W-XD%P,3IN@$HWS_FKUA]J
M_*O^)GG&H1QFT!3(.&))6X>O LK4*8#A0*GMG60].:9,-"H9[W4[)O[Q.T*/
MQX"^CJ;;[-Q%>JC::2Y:"QA% RC^.U+W>58/-/5.L>ZT*X;J@ 3*8&4BIY!(
MU%23BW6G&N-3X,N =YUS1H9;KMT\,O-9S8 R@LF-$C<*1@ECJ0;*7+1NK%T(
M+6!/@C0Y7\V@C# '2T>&E+]T'3'#/?=\J_':@6;45,I@^Z=DF3SF%)E*)!O'
M8@@&NF5R1@4HDYAB\D1]9.__><6N)S34&[*W?$*JK"(O*E;!R]L2A0]D/8-M
M3K"K\WT52UJ!\[%W?=W_UUL;NB=8F-1\ <HD,7G*TTR>1EX82HQ#V!7%[,(C
MC3V3K"O-.M->.?62OTO_6D.9!4XE5%%PNQQH.=^5GZ_/:DR9L[2\B<V8IE/R
MKC5&,%8,<4331 A-4W74TBUQ_JFO/Q7HWND.C]8K&19)0G4[FD5=!6E"4&,J
MB QPF2S2">&60Z*H.;+OY5O?(T 9F*=5A!NBPC0-GN7V+KM#8BS2K&)[N0*'
MH'F^!LK40)EG-&G*KX4$KZ'IILD7B@4-#B_V1R6='U/YR#W?Z%BSLR4R5*>,
MLL@P2?R*PMB4K&0)DPM<AK9",HYC5H]GP7&+3K'NC%\9"ZW9NB'UR2<T[+)$
MD%[$*E2J46A57XK<7E]+7Q).6@V4>4;;%;\@)L'?FMP;Z7<G -L+4 :L+6G:
M+1UR1RG@ ^X6+1($(CJPEHQYPUL^_< CIX$R-)O:CAIFU8O"E*EVI"KOJ622
M65@ +U@O(?6O-,_?\OJA51VO[0B\I<W_AN5M;_[#_W'+JVZ<?ON;WS/8_XG1
MH<^]\_"W/_V)7W_Y/XX]]M_<+/'B'-)T\"*%;0AY(TL8JRZ^6U^5*UZ<I=%J
MTNK+5H$RQ-JS>$#TFRH]/!R"CWWUX6NB!WWQNUGX*%/NAAZA,D;8,)%EQ)Y<
MSCHENW)$=()%<\X;[F*=HX'$V)_V['GP$3"N3:X5(%'(BQ#GL9NA]O_ET0(H
MOUKD_%^_\=MV>:<[.NJ,3[MC=['(%+%C1#8[@@:4PSC)9"J=WCG>&$T[PV.L
M=XKUY!Q=^_Z_5XT]]A3LO5A B*#$U7E]CGQ1"]!<RL80IE]U!6M;53F. S6F
M3%4+7;EO[7F0;.!J!F5$T24Q(VL:RKYPSA]?X/]KW4AS.-4:S[FD"4H]GG(F
MTDP9Q28P)JKS$DD;Y;$G42)4SB.Q(I;U=/:/O/N+15%40M1>PD(C7CBY6&OL
MY?ZR-3%A0=9CE#FG53)994B*WH!=B^@-8C<_?I*O[-S>*N5=,C%E8H)FF*$"
MJP!E2*]G$LLH.$I)1W>J29FNC\VXNT:#70/_\,5?+^"<\YJA@G]*F=/8VU^*
M7S50YBR]0@4,->TT4,80^ NM0:1QP=63:J'$^<(\V,4OWW&O<_7>U@2$M*$&
M+?@R\*NKU$ %'"/T_A"<S[C7S30HHZ$UFS_QP"RRWN"%(N1&.QV1.0%NSB5J
M.V=IN;,?$H] 3T$/*9X'W_%C#92I@3)GMYOR49,#_P0LHFNH>V8AI<!)!<'3
MY/,F?\>N#RV+['++!QV(.B-%@+($1"D;@F/$R@B%-4OIB29SRA2)3]?=>(]+
MRC5UC;1W#MSUT5^<M)3<:$O$4>M7IR2+QSEOCZROEVM"O]98MN& RWV6*EO;
M<W\CIG#QO?HLUI%"47^LR)LZ^P"U*/#2G$K*%4T24P8RU%2FA\@RI#Q"H;8)
M)J=]TL#G__,W)BF9X;RGK0EG7J[ZTHO[OOI:(C0!\3/D4NC@>6I%A/)_\5/^
MLAMVK5KVRC;?K6V^OG9_7\B[N=GSCM]?M</?_(XV_SN6A]X1:'GCJF4WM?E?
MOSSXNO;@:U:TO>95+\N\[4VY3>N/I),?FYGZS!<^]\@O?HZ$7ET'+0 )O$1+
ML1=#<?6E!2HL4,8FA5&SG\:405S3TLT1CI1A&EJIA/*;-VQX?TOGN%L^RN2[
M4!+58LI8&4S6Q!1-B^*=J)\-8FV.]<ZPR*A_S:Y;]WUDGC*[BE342<-^O*K;
MRU,@=6]EY)U^?''[OG8VX:^<K8TQ!U8&I>W9F)R?X+S[EIGZR#Y$ZJ0<F%-1
M48T%JPY4*I4DX3+33#GDC$^S2+HQ3HD/T"8<:>\9&CST16S3"JHH>;, _ED1
MXZ&DV6-AZ7JF>KS;IF8_G;@JGKH&RBQ=#UQ"9Q;&0.F<5TOUI=/LOSS-@B,#
M17J(.T$?C?-YG;_[D]_W=NUNB$ZR-4.@:<@S&._Q- @=V 1:U8(0@XEFP>]0
M#C%YBDD3=?%DN]+WW4=*10W9-705<5T!RB#P* C;Y1NXA(SB6=U*98H4>S\!
MQU0FS_+46GY3 OE6-0WP3V\;^K@O,LXB1$%"D0Y2)2"FC%792LIB"HU.>!(S
M[NZD)YQQQV<<T5Q#U_"-6_]Q%M.W:A+/WC2(!/^L;O[B_7(-E#E+6Y^-*8,1
MB"B>B-ZI!55;H+(L.*J9_-,/&AW1P:;N ^[P6!U5O631#(C)!,J EEY&2^-Y
M"#\I$\A@BF=9="P0V?>*#7]?-%%H@=9]@#)T-6P(3S/DL]SL97"H/,2$5V/Y
M$O;B7@-E:J#,,QBQ,"!P9'0PN#7*(D1-%],P*%!A\I+.'SG)>VXYU-395Q\;
MP_86K$9D*D%741:@#&G-H'XV7E1Z*>N.TJ>HFX8_\<B3+>&QCLZ^^[[UVP7+
M1%'\1*<RV:<X?XSSD+2Q!LJ4Q_)5#,I4S<T"1[=58"O>!C63%?(R#?Z9!Q[U
M17>Q*'*76/=X4T_&)8U19IV5U" 6#+%A8](8-NVQ&<_J@?ON?P0\%*@JE9$(
MG%;L!JOVZ\\PE'Z'C\6:I GE,W),2ZHQ"TZIR6=/\9/'^?O>\\CM[_A(R/^&
M]N";VD/O"/HW!7U]>/FWT6M+T+\%!_V;@H$-]%K?YE\?#-[1%KBC+7";W_N6
MCM!-RSIN#@;>TA["]Q>L?,?U:Z?V[?N/+WT)[AF*% J !N(M\%:K6N/\3W::
M>WW^7SW[IU9?VSL3^J73O634F<+]F&I1Y_=^\Y3_NCZOE/:$P6:']&,LPWKS
M5A'T[I0'5"EXZDXE*7@T%$T]PF)'ZN1<,#SX@<\_,L\QKU$Y*E4SH%!HT=FK
M8GU$Y!-CD)J&')2EWZZ?O9&NZ*-"SAD%083GA]ZG%<+D6LF$OB 02E0Q-[@Z
MQTU^3.-#[_^F9_5VB)Q%\RQVR!V?=D33@C@-J$XITS6G6>P0YH'N<=:;<]]P
MB'4F?4KZ13V#OYZEJQ@6*&,YG21$?\'&_YR[Y8Q1<]HHP&EQH ;*/.<&OIS^
MT)[ZR 9H2;, &@(DK57I"BJ);:UW8FT5?&G17:C."8>0UB#*(WS<X"_^N]'&
MZ &DHX*U05P895K,\*0@DV%$[G#+2;><06E%^1"3C[!(VM^]_?:Q?UZ@4VL&
M %BKUCV0 Y6(DNH5 LH\W=K+GLS3/Q 3"Y'B^4)A%@$?@W_Y>\>#70.T;F91
M\3J:<H33S;UWL3"BKR3@2H69@'9-UT>3]=$Q:O]I5_QPP^K!+_T$C)M2$>IU
MU(-BD3S?/=!MV69?\;O.<K>+>J@&RIR].2U?5WQ(OI>U'%F_CIZRCE  K\#Y
MK0?^(2CM]40S#BF/)3AJ*\@HX*QAG,K3X*R!*2/VA"FFC#D3F?I(\AIIWWWW
M/U[2,<Z+L!D:[V:)2FV*I?_L]WE9'!4-1:U(%D[OA#]38\J43:PF]'M>8R[/
MC<(1)(=4N,0&0O5"_/ZADSSRVJ'@==OJ$X=99,89R=;):4=DS)W(83Q"BEO0
M9(30C$6B(01G@N@+!)5&TBW2Z!]=?_#S#ZJV\IJF+B!7\;<&?YCSD'R'1ZE5
M7[+&<@V4@=V>%Y01[AU,]F-??M@?V\\2DZ3@FZF/)>LML<]).! 4/"<('U'T
MNEB&A<=9_*A7&?W\MYX _*\!A;''B;4-Q"BHFF+M3Q?]?P.)1MQ02T2*41'6
M0SZ%P9]XDO?W_TM[Z/5!_TTKEVU>V;&UM>6VMN"60&!;P-]WX:]E;0/MH?Z
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M&@;@G,$?>)A?$]WIDT?=,NH!804G.4/QG?Q.2IJ@K2!1.9!+[Y3S=>'Q0/?
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M[V)=*2:E&]=-.L)#]5"4R#+L'P[A1:I2(GT)4&PLSZ+)1B79%M[WRLWO>\I
ME*]$+J ]LE6"XV@7(6:8)>^0,[8KUG4KQW&@!LHL>4=<"A>PYU*R@:L#E,'*
M7AYJ-EV:\V(!9-%"\?_!XKO?]9WZ-;M;>_*.J VR5PGVE\4+"92AI$7*6W0H
MV6;IP)]=/_#+67Y*4.%03W"!<Q1O$Z",-<\@3=*NL7@I6,'%N@=1 MGD&B0\
MB"-<*I4X%;GK/_J59FF_,X8,)J:,.N11*^M$E+N*C[$X2?P2*$,%R"=89,P=
MS[1&#_SER_?.DB=#4K^BI6W#QN[T4OBJ@3*+TPNZ@4@]-Y%.?O/HA^I7;P5:
MUV.G2U#F. JKH]0&D64DB/JYI6E49NC-L^NS3!ZKBPZ'U@P>_=@C*(^M(S*J
M@;%<TA$@N40,YKDTEYC6R+4@^Q=.!K[CQQI31LS\-:;,>6VK*D7#MB?Z7U1>
M*IZ:^ZTMA8F\OZ(.B/TGQ_G:.X^V=.[QA#.>Q!% ,_!^"9%)9%F"5DF%P)I(
MDBEICS+ABJ18-Z6L*E-L[3L=/>]T=(\WO63SGZ[M_^+/C"<X_V^57R-MJ8$R
M5H"A!LI85FL;I;U/MF:W<C.5.'_<Y-?(V]W1429EG/&\*YYEW:/XCO0E@#+@
M/XOMF?4=]MHJC=ZP^1\03^.\:/ 2;8'*'ILHPHU[$+/J><?0[_(A@GDF_\YW
M9D/>O_F]%1O:O.L[ MN6MVUN:;G9VWI;,+@Y&-C>%AIH:=[2T;ZK+33@]VV_
MX,0EPFX"VUJ;U[>'P)0)>+>UA0#'M(=V>UNV!P,[6IJWM 7Z?:V;_=XMRT,[
MO8T;5RV[??8$AP NOA 1H<77"C':3UKVM^P#2_D_X!)41;; D?D2;J[(^<A[
MO[%<05U&%IUQ*#/NGAG6/>I.3$"Y"A0)X:P360;4ZS$(&7:.L\1=3)EV1)+-
MX?TK(MO>_]E'"M3) @JP#$"HC<!Q5XFH.T?@M(@J+KE)+&5;7H+G%K9D"7Q6
M<!G#0.2,0W'^).?[[_E*1]>.^NYQ=_PPDZ988AH#/#S2$$^Q,-'L$S/EW"6G
MDG++(NL!7#EW+%O?M6=%UY;/?K]8(%Z4: 4QM5 7"QJU7?ASR1M)/'+59:Q;
MJ1S'@1HH4]5"5^Y;>RXE&[@*0)D*&D)+*P:^Q91!Q!PEZD_H_/_\7;Y>RK!P
M"@6 A(@)K>:"]TIRLT(Q*E^5M)AWRTE_9."V@Q^<YWQ!;.[T!6[,JR5D,E5
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MVC'EA&3:UJI<7^ E=5[EGWC@1%M7/TJOKT49'0)E,B04D@(J#VSO")./H"Z
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M<;YIY%[_7VYI4W*.<)KX%S3=D,8X!6 %4R8+.:O(E$/*N^5,O9+Q*"D6'H-
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MS/WD@KD?PS'O(POG?GCAO ^>,O=?3IGWOC>=_:EKKOS2;WZ%50_);6 ,P@
M( !)1$%44XAYF+I5HO6#FW;,T10T&2J7(YPI\3IE TLX<PXD5%OTZ(U>(?E
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MFYF@3&V H9V< 65;IQK<3[^C()W)AS]_3Y>T!88TG'&C%$O!%1T5\MX4EW-
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MB0 1BH:]T- 5728, BR&T%41V[ C_IU%^[":C1:XC.WL""T]\4HX9LG@?SC
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MT1$FI[VAG?/#5SWX!Q!?R9.LJ7L2'X<NZ8 RPKP?/+EF]O XX7>/DMBHJ&E
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M3GE'I[QCEC+0%1EJ#_?/4@9]@0&OE/"HN18UWZ(BEYM)29><<6Y2^$-.J!/
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M7;7VG_,"VS#_5W4I52"I@8@=ZD7*V(IVO%/5SBHK58V J9@5WKZZ]I#%6)L
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M\O$U_S:GK!V)5Z-=6"O#_50]<'>6NCLC2* A0!EFL,)]XHNT%ZA-JVKOU;@
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M%-U'=C4D]B1/>D#:%MQ?L-4M^#XUY$03XDT#00JDC=GD:X&1RXHXQ\S20F.
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.@T4     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>May 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  01,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BioMarin Pharmaceutical Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-26727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0397820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">770 Lindaro Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Rafael<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001048477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  B!H5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  B!H5K&?.A1[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
M6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<
M_N\-L,+$CN'MB[\!4$L#!!0    (  B!H5JW":+K4@0  )T0   8    >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&ULE9AM;Z-&$,>_RHI652LEX2%^2FI;<IRD
MC>Z2\\5I3VK5%VL8[%5@EUN6./[VG<4V^'1X\+T)+#!__YB9_>^2X5KIUWP%
M8-A[FLA\Y*R,R:Y=-P]7D/+\0F4@\4ZL=,H-#O72S3,-/"J#TL0-/*_GIEQ(
M9SPLK\WT>*@*DP@),\WR(DVYWMQ HM8CQW?V%Y[%<F7L!7<\S/@2YF#^RF8:
M1VZE$HD49"Z49!KBD3/QKV^"C@THG_A;P#H_.&?V519*O=K!0S1R/$L$"83&
M2G \O,$4DL0J(<?7G:A3_:8-/#S?J]^7+X\OL^ Y3%7R141F-7(&#HL@YD5B
MGM7Z3]B]4-?JA2K)R[]LO7VVTW%86.1&I;M@)$B%W![Y^RX1!P&7_I& 8!<0
ME-S;'RHI;[GAXZ%6:Z;MTZAF3\I7+:,13DA;E;G1>%=@G!G?JK# )!O&9<3N
MI!%FPQ[DMMHV:_O[0]?@K]D8-]PIWVR5@R/*CWS#//^,!5[0_3;:1<8*-*A
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9=1,92L88!.R
M'<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3 QFU+BLX5>C(,
M=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,S
MQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN
M*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;
M4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ "(&A6B0>FZ*M
M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%
MKQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V
M\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\
M_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:
M(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    (  B!H5IE
MD'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E
M6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#H
MG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4S
MM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*
MJX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ
M R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L
M^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!
M4$L! A0#%     @ "(&A6D;'34B5    S0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  (@:%:QGSH4>\    K @
M$0              @ '#    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  (@:%:F5R<(Q &  "<)P  $P              @ 'A 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    (  B!H5JW":+K4@0  )T0   8
M      " @2((  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  (@:%:GZ ;\+$"  #B#   #0              @ &J#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    (  B!H5J7BKL<P    !,"   +              "
M 88/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  B!H5H<.&7J/P$  #P"   /
M              "  6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  (
M@:%:)!Z;HJT   #X 0  &@              @ ';$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  (@:%:99!YDAD!  #/ P  $P
M            @ ' $@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"   *%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bmrn-20250501.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biomarin.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="bmrn-20250501.htm">bmrn-20250501.htm</File>
    <File>bmrn-20250501.xsd</File>
    <File>bmrn-20250501_lab.xml</File>
    <File>bmrn-20250501_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bmrn-20250501.htm": {
   "nsprefix": "bmrn",
   "nsuri": "http://www.biomarin.com/20250501",
   "dts": {
    "inline": {
     "local": [
      "bmrn-20250501.htm"
     ]
    },
    "schema": {
     "local": [
      "bmrn-20250501.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "bmrn-20250501_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmrn-20250501_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.biomarin.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bmrn-20250501.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bmrn-20250501.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.biomarin.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001048477-25-000049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001048477-25-000049-xbrl.zip
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MT>:[<6X?O7VU?29=_T>=;U_]#U!+ P04    "  (@:%:^O-'*KL&   [,0
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MYFC803[XSNPP"B:\^SA>S)W1\&[Q1,0S/'"T]W"B^^C>M3_:^R]02P,$%
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MXO1:/^0(%'.*RYP2M'\ S2I+'!?9!7T[C)V$D].+M:'D$H/'OJ'0)DL?'G7
MI  E"O4K5[J:,:2;7 (I-2E'!U)%W6NB7C[S #8)A 6K'<&&>H$($2:.!WHI
M^^>OOW6N2S;P4MP?RINDB4[,P]"WNW0K/>6Y?A N3&$2L8A0.AOA8'CL89(.
M*?1=!>2< COV$8Y)?#.=*+"?['"T]&IPM4%<VHTK[$8*(K@&.%^Y<"YB_WPJ
MQ8> (K]O-\?1-8 \WZNMQOCOV &YV,#,9#K.FIRU]@_*0M9\(%H:^C9@/8PV
M0T-XQ0Q[?2##5+J/4YR=@,)-#.UGKH>O\"ZPZ@4\4-[M3@TM6>#$AXR>?3=
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M$,IIU#:5J52@V(K$&&2IKDNM.U$\ZBIJW#B1:0]Y%J4;!@=A'JQDB6<38W0
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MCZZ/<=A?/ P,Q00F8:&(D8F'NJJ\I._65L%=E"<WV'PL4D@H@]B2SO_D> N
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M@JDQT^_^\N6:Z;JNR%^,-LU'O]=52;WILZ;K%=P=0@7(R*H@?\;CC5])<#'
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MO&Q#3%DJ\Z6SA=C0 %$2Z0H8IIDJ# )6(#J%G:1\!WIFYA;BC:LWI919GUN
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M9 8'8 8MI:F7QNS6 *K5#*7=:I;,("O [H3C4.H@ULCRXWI@/)6C^21*OG
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M\@,\PHK0^?,X7$2^#X@1%V_*6E0\MZG-.:Z==<$#66O7Q%_$_R+[B3L ^KD
MY 4[*^ %2]ZO4%2EAHT)<A>&7)[^/M;=-C2E9:QVVI25_U( N^M[?E@!!6+
M;/=)!.%@$>LJ< P]%JZIZ[O'B--)2F@;2JNQ^]:"1T-B'=,D/P7SP2P Y0 L
M]=6)T<7#B:;>5M1F6<!V>\V5&C7@6GE+_<DQD5V!\')#SQ\=$56IBM;$PM!E
M-YEM@E37E$9]]];!T5"6+.UA3OD3CHG(6JI27]-1L"2QC9I; $#7] 4\$(%I
M]3P2F*RTO#&!=;GY^."#9FE5XN7UZ+_SUZ7\Y02+=,5H-)5V;4V$]:MA<.@H
MFJ*?$HI30RN+6+P*C->>:[[(7W^$5RDYUH0^>^[#,;O*ZK6&TM1V[]DY&56(
MRO/K91^:3:KY#&$-(X4-'8[<T+7H1HT:6!Z;TTQ5:FB+EM5YMWOYI\/_NV^Y
M>30D-]L)+C@V,M.,IJ*O2:LKB6P3@-;KBM8LI5KV[FJ>9SW;CG-$1(6Y+FI[
M=1G)DJAR"-"C(:H/HB? 9+:PV.,1>J45 V\ UR1>EA2V&4A;V+RA[!*\X=7/
MT1&7IM>51KWT<VQ1(U05O9U+HRO/5SZ+"6NWUSOYV/_2ZBVOWW0.R:.IJ&"#
MUFIK;DD*<I>UE?NKG*-AD;&MH;1;+:5MU(IZ)Y>7A*;/5YU?KCY?W5]=WK'.
M]0=V=W]S\<]_W'S^<'E[1ZVYF^?L\E^_7MW_L=E-W8I" #N[JLLZ9]%O4I.T
M)\?F7=NQ0UN4N4_["&T>\A&E+>.%#3=-/P+#/'4&92K4022!UE*TW%TOE6>_
ME[.OD1YP:),L?R6JCFW!13-ZS7D)O9-@Q\+$T&7ATJ_<?AGDN&M6FF-S*A_$
MGPIQ?(%NOA[-RR#'K0<YFIY+JT&]WA+=HXN_JK?Q&F"UFR077+1( %4/'^YX
M%"I</IF#O!!TQBQB,R6N*'BL:FVEL8>^>R?#&%10<5M[""P_,E-IUR92D91P
M5='KNE)?DPM=E#NT8S65X)3TFM)>HU25QM*ZHCRA9S[V/0>@%"0W39@&$8Y.
M.#$L\S&EZJO&0U3P^7>J445NO]?KJ+C,/YZGPKZO56LUE0VYSYZX$PDZ3%:O
MU92:_#_I!\"CL._Y,(T%C[3/F=I6E6:]KK1J&MVP8(>,9@.(S6@GK]A!@'<N
M^.U4-P'X;BA,+-OM3$ICR-K01Z!7M,NZ3EL$9BX#N/)I"'5@H5CA'K2T(;>M
MBNTRDP]MT-J.R ZJ*\VVH>BUDLBV"%+@X4JM<7 G27%(#60HK'TT;IF#LI3U
MA6.Q[HB%?<&N/?=_$:RN9X, '*<%X&O"#3A2*?OJ</>("/-,5;'<VMN2(K<#
M2TW;*2R/AA0[IAD-(H=C)RM/EH4"*O-%'P@--$QFN_"W8&>.%P1S "TPCJAM
M1:WO7CLZ&9H#TZ4LP?9"NK-$SS;M8[J'.VN#[=LNA=E6A!DH[(UV/6?2+,].
M]F"IKRV+S_T8G+9HYNF*45^=?%QZT/=T&(UZ4VFW"^5!SSV1IV[2R$6:G>BW
M@EOY ,519CMES*W+%_,JD2K?2)6O%+IDOF2)\@[K$-EA!\M(VZ"_;3)*?.?7
M2H@F;BE;P4_VA$NR#:3Z5F+1_,^D3=Q4ETZ#=;G#71,DU;/P,?+2MY_ [NOY
MWH#<G7%327;AN81R9!5^M%UX!];*[D+X@"I3HCO&B2SXUG;I35-Z4F.!%[".
MZT;PQJT8>G[(/)=]]/P!4VN5?[*>Y],K(\%])ER+/*N+5JNPGNW M\]VV*<W
M[BXO:"C1]2/NC^33^!QV ES>YO54.PZWMM%Q6*V]>?_JEL--;3C?<KCL++RC
M%2_I+'QW#_]\N;R^OV,W']E%Y^X?[./GF]]SVF/XON\+P;[ <_V 71*7F.[\
M>;B.PVM3O-=W'-Y[7^&,:WYA7^$EA)RO;L3M:J-MO*@;<;/:5EO;;_"K5YO-
MYM:[$<.4N^A&C(O-UI%YC7V_-(YRK:[7SD>%A[7\J[:.?VW2G??EX-HP?"['
MU3(R-GK>5F#B$8#+V"J*Y<!#L'BG$R6&?;R]^<)NOE[>=NZOKC^QSL7]U6]4
M7V6O>8!;H=:7)^1N$@);A%-?DN\IPC@<H*S]<9BV5G6ET<I;^=#R[/>Q[E9+
M:30.W@.YN+RK8_TWBKN[L-##MJV>:]I@!KECIH:?XU_4\WWH>T\V*H_=$</^
M%3R$[3&.4?<%K4"5]>PD[6K5?-[]?1!#.#M;AH!29:J!!TOZBSXXH@ :#2.*
MRUKLVX-G4]'W4!?@)&CPVG,KQ"1MM+M$$#+Q#>.RY]3" N-+HU$6D=@:,->%
MOI24ESUHU!<D^KP>L^R *C7BU=QQ-J\[4Q6]H951I-L I:;4:SL%Y4D0(&5Q
M5[H\$!9=O2?92$=$='I3:=9*X;>]Z,^6HAD';P)T'.3WB=LNBKN @^4.(M#U
MW-XX2N;H>II04(]V7I+B]O0)*LE02L'7]I<<#+GMH[:)1'AT=*<I[<;JV..2
MZG+(QDZ"],:Y\(G/FG\[JCI]6DLQM-+ON45X[K[FX4D0WJ^N+V#NOS!LV_/A
M&Y>);V:?NP^"/8!:>D0T2&J2UBC]+EN"9:MF'%#E+%SIW./@%U16]ZB8@J(U
MRO(TVRF=NWOKXB1H[(+$+R9%I6,TR!REV(!"=PS;Z(BT>K69RR,:=Q/SA2GL
M)TPB.+:> V?UIE)O[]2K=#*L\4Q7]-9.-<^3H+HK]TFXH>=GJ7=2&-30#$77
M=UH&YW3(3&TH+:TPCO#<TIGLG9$T03HZ1_A90]%W6T;QA"@. Q#UDN*V0G''
M1VFJTM!VZB4Z(4K3%%4O9=NA^D 7&74TI5$O-<SM&,58 ;2TY,KN;-DB+LID
MEVV&<"IZK5@1AWHSI_1WG34A\#6590M3R51M&HK>7MWTKZCMJPMS"$9#:3=7
M5Z[?[1D<09)PMK(65]>_7=Z]L*Q%\2Z2\L=\OT:^V>>!H#)>P("![88CA0T=
MCMXV,$>PON\0XU"/2!="WVRST2JMD*T8= U%/6CT37&)[PL/(S]57IL[D@Z/
M,]6PV<0PK=($V9JFJ*M*73]X/YCBDM^4[#M.FCMKM16M67J]M^3U5I5&XY!=
M8@I,:[YG"F$%LB!WF5Q84N!+)![E%I8"[[4"3\J[D+L/-MTZE817$MX:->+
M2;V%R[ HW(*/["XA"F0##ZG6G^ ]PIG64C1]J8^KO$+8N;5@ /R7WLZ7UP=;
MN3[X>'7=N;[8^?7!3FM?G]B%PY0A*+X)W[1C%PQ_YCY\ 9L2?MQ7$'/PA8O-
MC.A*HE12M\6+7X[1Q8-T4U';A4D'S!_%WF/]"S;D(*"HLQ@H5G$9YZ#/?<'
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M(9V,Z;FF[>#V:24I8-[^^)W>.O^0;"V8/H"[3_1U)_6U+]:!?>&0BX=3$&L
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M,[T21.U,-PZWBS'P-L' U$7$%#:F/]^BG5"OMNH9UKT B1&<%;VJXNNSEW[
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M&Y1+OVDEAH9>-=3MMPUL5IO-EU4W.*913[5QXFLS4I:ZM=7%?NV<I@KFO K
MRX_A2%(YMU8>(,=[C+L18=%D<B-.U>,\]LUG+&M0Z#V^]H#S)STV9G S2O&J
M+.']\+S3&R1_N'&,5T0KTF2O7-,;"-;SO0&[&0J?XH/+I-D#9?X86XP?RV'F
M3YZC2Q8?B5ZKUH[J3/8&N;ERHB4/V<>Z6ZVC0M<C8"&J7CVNA,[#L9!"J(6[
M4B EBNMYO(4[WBS._"'-3M%+J^<1O4XHC5'?:<>*(P!0O;JZM4H)H?KJ"($2
M0.T]HU">9<0)2I/.P(,5_"4EB-=CMAMR]\'&:W<>!&*%"E,\5%_=(*9D!;5J
M*6_7!927 %K=-;.JE=(D+W<GR_+$-6._>>*?N.UB,V%L(HPR!K;>LUWNFC#P
MC)39PIIVGBFNE9GBI\G<2BAEJSU4VU<.<A&!4ZV7&=JE;,Q>0X451S26-51.
ME:V54,KDSB[AL\;_L%\/39[%WM8$9/X6?,I/EH=5H">+$]*ZINK)1F&M98[T
M4>5(:XU&(7*D)^K*SA P)R>BU]?<LQSH2/8&@&7!L"7G.2K.H]:+43WD=#B/
MIE=S63#C<)RG$'KHAAIK4B1C"U!5M4SU)"1.S?]<6GCC9>4Z7O;6="$(C!B>
M+IJM5^NISWRY+?GAZK(=%:TI<R3W6Z3"J-8-*IBP:9&*9J.JUC(74\@\;+O:
M;ALO&G7U=T:MN9.U-K*.6AR*WT5U@G99(R('IW DZ?5;JQ%Q H#*4FLAMWPH
M>61?1026C;$=3,K]"G.+!R\&:0ZL]Q7U 3[86.;-8I=?[\J$WD.LNU9MEXUG
M2TS;"Z89QY6HG /AL'<Q4F8);^O1PJ%(<5*P3BBAMU95VSF3IH6&IG8H:);L
MH,S(W H&U_8;%'GD_*"VWP3.X^$'A<L;R)!35Z3,@3*GKF1O:W.G@+^5R5/'
MS]K*MM+YIL.2L6U?;RNK)F1D;OE;<%&>/'*I\=D+ E2(;?=)S/A5BR GC..3
M$P=D:T<H) XK=8O.SG+L[XN3LT+^C8E>3YC4A(1GN!TJ'@X?R(([0FZ D&R5
MMO NM9I#)&JFXHN*Y+VK+U%>DMOZ55DEM9--[=I@YSGD0&I5?47S\NQ[WVM,
M58FI1XBIM6I3+1ZFYE34%B"Y+$ZJPM.:R_8RQB; 3!*7'"M#'MGFP[X23*U,
M4#I3WRX#U 4@']X6\H$7@3W!!GS$7 ^6%0V8YS-? &*:$0A\P:P(#!&/460=
M;*Y:5&!H;]DR:-R*H2\"-*P89T,^0AN+A4"F#\('S:L[@H_#ONU;\*4?COX&
MCX4(OD'<'I(#P!X06IX/CPZ'OO?$'08K%T$(Q,)(=8*! (PPT9/M18$S0I9A
MS4=R%!:^^E)DN^\#<,>H]@PPA6V;3F0)W#^[^_3C=WKKO!-?[<1'P8*U5?!2
M8 W[@EUX ^!8>#J8,0//^$//1PRV7=!@27<-:"Q\&(#MF3:][OD/W(V#:^#8
MX,1% !P9+6_/+_"!&$L/)(WO+K,!;+9/N.S$#E-@\178W:.0>:SB?Y$= L(*
M$\ ?V@)!;Z+\H_.[ 7CZ>*+HLCB+ Q3?*LP586%A5U\*N[%=]CN](*Q*!_'T
M08P-M;L^!^BRFR@,@+9Q6Q+GU7:C6D>NX& 4%R*BVFY7]?$G@7P/D(XP-*3\
MQ8%'^8L"\Q?9.'D1,;Q.0R"J*T@=0V$BACLCA3WW;7B,YH23 Y2."63R%-MX
M!W#..,00P.E9 8OQ1UAK3SC6H$BPIPY=K<^>^NN3KM?+Z_B0"<'F#=LX5Y@4
MQ/1;\19JDU=X%Y@W@&KI*ZL7K#>VA<YJ+1,^J]J,,9[^V?6L$?S3#P?.^_\/
M4$L! A0#%     @ "(&A6L<7_LNM#P  E6$  !$              ( !
M &)M<FXM,C R-3 U,#$N:'1M4$L! A0#%     @ "(&A6BS+,"UW @  6@<
M !$              ( !W \  &)M<FXM,C R-3 U,#$N>'-D4$L! A0#%
M  @ "(&A6F1 )*8R"@  >%4  !4              ( !@A(  &)M<FXM,C R
M-3 U,#%?;&%B+GAM;%!+ 0(4 Q0    (  B!H5KZ\T<JNP8  #LQ   5
M          "  ><<  !B;7)N+3(P,C4P-3 Q7W!R92YX;6Q02P$"% ,4
M"  (@:%:/SCA:YM,  !9$@0 'P              @ '5(P  96%R;FEN9W-R
L96QE87-E+3%M87DR-65X.3DQ+FAT;5!+!08     !0 % %$!  "M<      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>bmrn-20250501_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bmrn-20250501.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001048477</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-01</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001048477</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">BioMarin Pharmaceutical Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-26727</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">68-0397820</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">770 Lindaro Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">San Rafael</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94901</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">506-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">BMRN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
